NLS Pharmaceutics Ltd.
13F holders, Q4 2024 (December 31)2holders
0new positions
0sold out
$2.11avg. 13F price*
At the end of Q4 2024, 2 institutions reported holding NLS Pharmaceutics Ltd. in their 13F filings, unchanged from Q3 2024. 0 opened new positions and 0 sold out. The largest holders were BVF Inc. ($303K) and UBS Group AG ($17K).
- Company
- NLS Pharmaceutics Ltd.
- CUSIP
- H57830137
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q3 2024 → Q4 2024: 3,573 shares bought, net +3,573 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| BVF Inc. | 0.01% | No change | 143,676 | $303K |
| UBS Group AG | 0.00% | Add +75.7% | 8,292 | $17K |
"% of holder's portfolio" is NLS PHARMACEUTICS LTD's weight in each manager's 13F, not the share of NLS Pharmaceutics Ltd. the manager owns.